By Sten Vermund, MD, PhD, Professor of Medicine, and Director, Institute for Global Health, Vanderbilt University School of Medicine
With final preparations underway for AIDS 2012, the world’s spotlight will soon turn to Washington, D.C., for this important conference as it returns to the United States for the first time since 1990. As local scientific partners, the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA), along with the IDSA/HIVMA Center for Global Health Policy, looks forward to the broad array of HIV clinicians, researchers, public health officials, advocates and many others who will gather in D.C.
AIDS 2012 will provide an unprecedented opportunity to share new HIV research and knowledge from around the world. We hope it also serves to renew the world’s commitment to move forward to begin to end AIDS. Breakthroughs in treatment and biomedical prevention now offer the promise of a future in which HIV-infected persons can live relatively normal lives and transmission will be rare. The major question for AIDS 2012 attendees is whether the world can maintain the political and economic will needed to transform these hopes into reality.
In addition to the great conference programme, we hope you will make plans to join us at a special related symposium exploring some of these issues, “Treatment as Prevention: From Science to Implementation,” on Tuesday, 24 July, at the American Association for the Advancement of Science (AAAS) Auditorium at 1200 New York Avenue, NW, in Washington, D.C. The nearest Metro stop is Metro Center, and AAAS is located between 12th and 13th streets, NW, and between H and I streets.
Co-sponsored by HIVMA, the Center for Global Health Policy and AAAS, the event will bring together a diverse group of stakeholders from the domestic and global communities to discuss the latest science on HIV treatment as prevention and identify challenges and opportunities for implementing it on a larger scale in the U.S. and in Africa. A reception begins at 17:30 p.m., followed by the programme (see below) from 18:30–20:30 p.m. Contact HIVMA with any questions, and learn more about our related events online.
Panel 1: An Update on the Science: Examining Impact Through Observational and Experimental Study Designs (moderated by Sten Vermund, MD, PhD)
HPTN 052 Update and Overview
Myron Cohen, MD
J. Herbert Bate Distinguished Professor of Medicine, Microbiology and Immunology
University of North Carolina at Chapel Hill
An Overview of PEPFAR-supported Treatment/Combination Prevention Trials
Nancy Padian, PhD, MPH
Professor, Department of Obstetrics, Gynecology and Reproductive Sciences
Director of International Research, AIDS Research Institute
University of California at San Francisco
An Update from the ANRS Test and Treat Study: Kwa Zulu Natal, South Africa
Africa Centre for Health and Reproduction Studies
Assistant Professor of Global Health
Harvard School of Public Health
New York City: The Science Behind the Evolution of a Test/Treat Policy
Blayne Cutler, MD
Director of Prevention, Bureau of HIV/AIDS Prevention and Control
City of New York
Implications of HPTN 043 for the Way Forward in Treatment as Prevention
Thomas Coates, PhD
Director, UCLA Program on Global Health
Michael and Sue Steinberg Endowed Professor of Global AIDS Research, Division of Infectious Diseases
University of California at Los Angeles
Panel 2: Reactions: Implementation Issues and Strategies
(moderator: Barbara Jasny, PhD, Deputy Editor for Commentary, Science/AAAS)
Implications of Treatment as Prevention Policies from the Perspective of a Community Activist
Dazon Dixon Diallo, MPH
President, SisterLove Inc.
Realities of Implementation from the Frontlines
Jean Nachega, MD, PhD, MPH
Professor, Department of Medicine
Director, Centre for Infectious Diseases
Faculty of Health Sciences, University of Stellenbosch, South Africa
Implementation Issues in the U.S.
Donna Futterman, MD
Professor of Clinical Pediatrics
Director, Adolescent AIDS Program
Albert Einstein School of Medicine
Implementation and Resource Issues from the Perspective of an Economist
John Blandford, PhD
Chief, Division of Global HIV/AIDS Health Economics, Systems and Integration Branch
Centers for Disease Control and Prevention